Fairmount funds exercise Apogee stock options
Apogee Therapeutics, Inc. reported option exercises and related share movements involving Fairmount-affiliated entities.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Apogee Therapeutics, Inc. reported option exercises and related share movements involving Fairmount-affiliated entities. On 2026-08-07, options to acquire 31,838 and 10,370 shares of common stock were exercised at strike prices of $17.00 and $43.85 per share, respectively. The resulting common shares are held indirectly through Fairmount Healthcare Fund II L.P., with 51,166 shares reported as indirectly held for each of Tomas Kiselak and Peter Harwin, who, along with Fairmount, disclaim beneficial ownership except to the extent of their pecuniary interest.
Insights
Analyzing...
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F2, F3 | 31,838 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F4, F3 | 10,370 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 31,838 | $17.00 | $541K |
| Exercise | Common Stock F1 | 10,370 | $43.85 | $455K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (4)
- F1. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- F2. This option represented the vested portion of the total right to purchase 47,758 shares of the Issuer's common stock, which vested in three approximately equal annual installments beginning on the first anniversary of the 7/13/2023 grant date.
- F3. Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Harwin held the options reported herein for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Harwin was obligated to turn over to the Adviser any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaimed beneficial ownership of the option and underlying common stock.
- F4. This option represented the right to purchase 10,370 shares of the Issuer's common stock, which vested on the one-year anniversary of the 6/5/2024 grant date.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
beneficial ownership financial
pecuniary interest financial
director by deputization regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many Apogee (APGE) options were exercised and at what prices?
What are the reported indirect holdings after these APGE transactions?
Were the Apogee (APGE) option exercises under a Rule 10b5-1 plan?
Who is attributed with these APGE transactions in the Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.